World Journal of Pharmaceutical Science and Research
www.wjpsronline.com
Review Article
ISSN: 2583-6579
SJIF Impact Factor: 5.111
Year - 2025
Volume: 4; Issue: 3
Page: 878-888

EXPLORING THE IMPACT OF CERVICAL CANCER: A LOOK AT PREVENTION, DIAGNOSIS, AND THERAPY

[1]Nameer, [2*]Nandini Chaturvedi, [2]Nidhi Chaudhar, [3]Ashok Kumar, [4]Dr. Amandeep Singh

[1]Student, School of Pharmaceutical Sciences, Jigyasa University (formerly Himgiri zee University), Dehradun.

[2]Assistant Professor, School of Pharmaceutical Sciences, Jigyasa University (formerly Himgiri zee University), Dehradun.

[3]Associate Professor, School of Pharmaceutical Sciences, Jigyasa University (formerly Himgiri zee University), Dehradun.

[4]Principal & Professor, School of Pharmaceutical Sciences, Jigyasa University (formerly Himgiri zee University), Dehradun.

Article Received: 05 May 2025 // Article Revised: 26 May 2025 // Article Accepted: 17 June 2025

***Corresponding Author: Nandini Chautrvedi**
Assistant Professor, School of Pharmaceutical Sciences, Jigyasa University (formerly Himgiri zee University), Dehradun.
DOI: https://doi.org/10.5281/zenodo.15773471

How to cite this Article: Nameer, Nandini Chautrvedi, Nidhi Chaudhary, Ashok Kumar, Dr Amandeep Singh (2025) EXPLORING THE IMPACT OF CERVICAL CANCER: A LOOK AT PREVENTION, DIAGNOSIS, AND THERAPY. World Journal of Pharmaceutical Science and Research, 4(3), 878-888. https://doi.org/10.5281/zenodo.15773471

ABSTRACT

Cervical cancer stands as a significant global health concern, ranking as the fourth most common cancer among women worldwide. Despite its preventable nature, it contributes to over 342,000 deaths annually, with approximately 90% of these deaths occurring in low- and middle-income countries (LMICs). Caused primarily by persistent infection with high-risk strains of the Human Papillomavirus (HPV), cervical cancer exemplifies the intersection of virology, immunology, public health, and gender equity. Advances in preventive medicine—including HPV vaccination and cervical screening—have demonstrated considerable efficacy in reducing disease burden, yet access to these life-saving interventions remains unequally distributed. Cervical cancer progresses slowly, often taking 10–20 years to develop from initial HPV infection to invasive cancer. This prolonged progression provides a valuable window for prevention and early intervention through screening methods like the Pap smear and HPV DNA testing. However, despite this opportunity, awareness levels and health-seeking behavior remain low in many populations due to stigma, misinformation, limited infrastructure, and socioeconomic disparities. Simultaneously, regular screening has emerged as a cornerstone in reducing mortality. Innovations such as self-sampling kits and visual inspection with acetic acid (VIA) have shown promise in improving accessibility, especially in rural or under-resourced regions. Nevertheless, infrastructural barriers, lack of trained professionals, and irregular follow-ups persist as hurdles to effective implementation.

KEYWORDS: Cervical Cancer, HPV, Vaccination, Screening, Women's Health, Prevention.

INTRODUCTION

Cervical cancer is a malignant neoplasm that arises from the epithelial cells lining the cervix—the lower part of the uterus that opens into the vagina. It primarily occurs due to a persistent infection with high-risk strains of the human papillomavirus (HPV).[1,61] Among over 200 HPV genotypes, types 16 and 18 alone are responsible for nearly 70% of cervical cancer cases worldwide.[5,29,59]

The transformation from HPV infection to cancer typically involves a multi-step progression—from cervical intraepithelial neoplasia (CIN) to invasive cancer, which may take years or even decades.[3,57,58] This latency period offers an excellent opportunity for screening and preventive care, especially through regular Pap smears or HPV testing.[30] Despite this potential, cervical cancer continues to pose a global health crisis, particularly in under-resourced areas, where the majority of cases are diagnosed at advanced stages.[6,56,2]

Global Epidemiology and Burden

According to the GLOBOCAN 2022 report, there were approximately 604,000 new cases of cervical cancer and 342,000 deaths globally, with India, Sub-Saharan Africa, and Southeast Asia shouldering a disproportionate share.[7] This makes cervical cancer not just a biomedical issue but also a socioeconomic and political one.[7,28,52] The lifetime risk of cervical cancer is significantly influenced by access to preventive healthcare services.[47,55] In high-income countries (HICs), routine screening and vaccination have lowered the incidence dramatically, while in LMICs, limited healthcare access continues to cost thousands of lives annually.[8,48,50]

HPV and Its Link to Cervical Cancer

HPV is the most common sexually transmitted infection (STI) globally. Nearly 80% of sexually active individuals will acquire an HPV infection at some point in their lives.[31,32,71] While most infections clear spontaneously, high-risk HPV strains can persist and lead to cellular mutations, especially in women with compromised immune systems.[9,27,46]

Risk Factors and Vulnerable Populations

Several sociodemographic, behavioral, and medical risk factors increase a woman's susceptibility to cervical cancer. These include:

- Early onset of sexual activity and multiple sexual partners
- Immunosuppression (e.g., HIV infection).[10]
- Smoking
- Long-term use of oral contraceptives.[11]
- Lack of access to reproductive healthcare.[12,60]

Notably, cervical cancer is most prevalent among women aged 35–55, with the highest mortality rates among women above 45 years.[13,73] In regions with poor healthcare infrastructure, it is often diagnosed at Stage III or IV, significantly reducing survival prospects.[14,41,66]

Current Prevention and Screening Programs

The dual approach of vaccination and screening has proven to be the most effective in controlling cervical cancer. Screening methods include:

- Pap smear (cytology-based testing).[14,65]

- HPV DNA testing
- Visual Inspection with Acetic Acid (VIA).[15]

These methods can detect precancerous lesions early and allow for timely intervention through cryotherapy, loop electrosurgical excision procedures (LEEP), or conization.[16,39,68] Countries like Rwanda and Australia have shown that national HPV vaccination programs, when paired with organized screening, can reduce incidence rates by over 80% within a decade.[17,34,42]

Challenges in LMICs

In LMICs, cultural taboos, gender inequality, and weak healthcare systems are major barriers to effective prevention.[33,18,68] Low literacy levels and misinformation fuel myths around HPV vaccines and reproductive health, while financial constraints often discourage women from undergoing routine checkups.[35,19] Furthermore, the COVID-19 pandemic severely disrupted cervical cancer programs globally, causing delays in screenings and halting vaccination drives.[20,35.67] This setback threatens to reverse years of progress and emphasizes the need for resilient health systems that can withstand such shocks.[21,22]



Figure 1: Global Cervical Cancer Incidence Rates (2023).

CONCLUSION

Cervical cancer is a preventable and treatable disease that continues to claim the lives of hundreds of thousands of women each year, particularly in low- and middle-income countries. Despite decades of research, significant advances in vaccination, and improved screening methodologies, the burden of this disease remains unevenly distributed across the globe. It is both a medical and social injustice that cervical cancer persists as one of the leading causes of cancer-related deaths in women, despite the tools available to prevent and cure it.One of the key strengths in addressing cervical cancer lies in our understanding of its virological origin—HPV. The discovery of the link between HPV and cervical cancer has revolutionized prevention efforts through the development of prophylactic vaccines. These vaccines, which provide nearly complete protection against the most oncogenic HPV strains (types 16 and 18), have been shown to significantly reduce the incidence of cervical intraepithelial neoplasia and, by extension, invasive cervical cancer. The success seen in countries like Australia, where vaccine uptake exceeds 80%, serves as proof that elimination is achievable through robust public health infrastructure and community engagement However, gaps remain in health literacy, access to services, affordability, and cultural acceptability. The greatest barrier to cervical

cancer elimination is not technological—it is social and political. Millions of women do not have access to the basic healthcare infrastructure required for HPV vaccination and routine screening. Many are not even aware of the disease or its preventable nature. In areas where the healthcare system is fragmented or underfunded, the delivery of timely and consistent preventive care is compromised. This is especially true for rural women, minority groups, and those living below the poverty line.

Moreover, the stigma around gynecological examinations, vaccine hesitancy, and religious or cultural opposition to HPV vaccination campaigns create additional layers of resistance. These barriers demand community-based solutions—strategies that involve educators, religious leaders, healthcare workers, and policymakers in creating a culturally sensitive approach to cervical cancer prevention.

The COVID-19 pandemic also disrupted global health systems, causing backlogs in cancer screenings and delays in treatment. This has underscored the importance of building resilient health systems capable of adapting and continuing essential services even during times of crisis. Addressing cervical cancer holistically means integrating prevention into a broader vision of reproductive and women's health. It means offering comprehensive sex education in schools, expanding health insurance coverage to include HPV vaccines and cancer screenings, and investing in workforce development to ensure that nurses, doctors, and technicians are trained and available. It also requires empowering women to take control of their health by ensuring they have the knowledge, tools, and confidence to seek care. In conclusion, the path forward is clear. The science is sound. The tools exist. What remains is the global political will to prioritize women’s health, the funding to scale up proven interventions, and the societal shift to break taboos and elevate awareness. If we act decisively now, cervical cancer can become not a leading cause of death—but a triumph of prevention.

Future Prospects

The fight against cervical cancer is poised to benefit from a confluence of technological, scientific, and policy-driven advancements. The next decade promises innovative breakthroughs that can enhance prevention, improve diagnosis, expand treatment access, and ultimately eliminate cervical cancer as a public health threat.

1. Advanced Vaccines

Current vaccines like Gardasil-9 already cover the most dangerous HPV strains, but future vaccines may offer protection against a broader range of HPV types. Research is ongoing to develop therapeutic vaccines that not only prevent HPV but also treat existing infections and precancerous lesions. Additionally, mRNA vaccine platforms, proven effective during the COVID-19 pandemic, may be adapted for HPV immunization, enabling faster and more flexible vaccine development.

2. Cost-Effective Solutions for LMICs

The high cost of vaccines and screening technologies continues to be a barrier in LMICs. To address this, organizations like GAVI and the WHO are working on affordable vaccine procurement, while companies are investing in low-cost, point-of-care HPV tests . Innovations like solar-powered cryotherapy devices and self-sampling kits also offer promise in resource-constrained settings where access to labs and clinics is limited .

3. Artificial Intelligence in Diagnostics

AI and machine learning tools are revolutionizing medical diagnostics. AI algorithms trained on cytology slides can now detect abnormal cells with accuracy comparable to human pathologists. These tools can be deployed in screening programs to enhance early detection, especially in areas lacking trained specialists. Additionally, mobile apps integrated with AI are being developed to provide real-time guidance for VIA (Visual Inspection with Acetic Acid), expanding screening reach to remote areas.

4. Telemedicine and mHealth

The expansion of telemedicine during the COVID-19 pandemic has opened new avenues for cancer care. Women can now receive consultations, schedule screenings, and obtain results remotely. Mobile health (mHealth) platforms are also being utilized to deliver reminders for screenings, vaccine doses, and follow-up visits, improving compliance and outcomes.

5. **Global Policy Momentum**

The WHO's Global Strategy to Eliminate Cervical Cancer has galvanized international support, with countries aligning national health plans to meet the 90-70-90 goals by 2030. Nations like Rwanda, Vietnam, and India have launched or expanded free HPV vaccination campaigns and integrated cervical cancer services into universal health coverage frameworks.

6. **Community-Based Interventions**

Future strategies will increasingly rely on community health workers to educate, vaccinate, and screen. Training programs for female health volunteers, peer counselors, and school-based vaccination drives are already showing success in improving uptake . These grassroots approaches are vital in bridging the gap between healthcare systems and underserved populations.

7. **Equity and Inclusion**

Ensuring equitable access for marginalized communities, indigenous populations, transgender people, and women with disabilities will be a central focus of future interventions. Programs will need to adopt inclusive policies that respect cultural diversity and address specific barriers faced by vulnerable groups.

8. Integration with Broader Health Systems

Cervical cancer initiatives are being integrated into broader reproductive health and primary care services. This includes family planning, STI testing, HIV care, and maternal health programs—providing women with holistic, streamlined healthcare that increases efficiency and access.

9. **Next-Gen Research**

Ongoing research into the molecular biology of cervical cancer is shedding light on novel biomarkers, genetic predispositions, and targeted therapies. Precision medicine approaches may enable personalized treatment plans, reducing side effects and improving survival.

10. Elimination within a Generation

With strong political will, community support, and scientific innovation, cervical cancer can be eliminated within the next 20 years. This will be a landmark achievement—possibly the first cancer ever to be eradicated through vaccination and organized screening. But it will require global solidarity and sustained investment.

REFERENCES

1. Krati, Dr. Martolia Jaya, et. al, A comprehensive review on in-vitro methods for anti- microbial activity, IP International Journal of Comprehensive and Advanced Pharmacology, 2024; 9(3).
2. Neeru, Shilpi Kashyap, Esha Vatsa, Jitendra Singh and Ankush Sundriyal "Determination of Total Phenolic Content, Total flavonoid Content and Total Antioxidant capacity of different extracts of Roylea elegans Wall. (aerial parts)" World journal of pharmacy and pharmaceutical sciences (WJPPS), 2016; 5(6): 1884-1891.
3. Neeru, Esha Vatsa, Jitendra Singh and Ankush Sundriyal "Pharmacognostic Standardization Parameters of Roylea elegans Wall. (Aerial Parts)" International Journal for Pharmaceutical Research Scholars (IJPRS), 2016; 5(2):133-140.
4. Kundan Singh Bora and Esha Vatsa "Pharmacognostic Evaluation of Dendrobium macraei Lindl." Universities Journal of Phytochemistry and Ayurvedic Heights (UJPAH), 2016; 1(20):29-36.
5. Amit Sharma, Bharat Parashar, Esha Vatsa, Shilpa Chandel and Surbhi Sharma "Phyto chemical screening and Anthelmintic activity of leaves of Cedrus deodara (Roxb.)" World journal of pharmacy and pharmaceutical sciences (WJPPS), 2016; 5(8):1618-1628.
6. Amit Sharma, Surbhi Sharma, Shilpa Chandel, Esha Vatsa and Dr. Bharat Parashar "A review on Morchella esculanta: Therapeutically Potent plant" World journal of pharmacy and pharmaceutical sciences (WJPPS), 2016; 5(9): 685- 699.
7. Esha Vatsa and Kundan Singh Bora "Memory Enhancing Activity of Dendrobium macraei Lindl. in Swiss Albino Mice" British Journal of Pharmaceutical Research (BJPR), 2016; 13(2):1-11.
8. Vatsa Esha, Chandel Shilpa, Parashar Bharat, Neeru "Physico-Chemical and Phytochemical Evaluation of Dendrobium macraei Lindl. (Whole Plant)" International Journal of Pharmacognosy and Phytochemical Research (IJPPR), 2016; 8(11): 1801- 1811.
9. Esha Vatsa, Mehak Aggarwal, Shipra Gautam "Formulation and Evaluation of Polyherbal Facial Scrub" Just Agriculture multidisciplinary e-Newsletter, Article ID: 023, 2021; 1(9): 1-6.
10. Shipra Gautam, Madhubala Thakur, Mehak Aggarwal, Esha Vatsa"Azadirachta indica- A Review as a Potent Anti-Diabetic drug" Just Agriculture multidisciplinary e-Newsletter, Article ID: 98, 2021; 1(10): 1-6.
11. Esha Vatsa, Samriti Faujdar, Nidhi Sharma, Shilpa Chandel, Mehak Aggarwal"Dendrobium macraei Lindl.: A review on medicinally potent orchid on the basis of recent evidences" Chinese Journal of Medical Genetics, 2022; 31(3): 560-571.
12. Krati, Babita Rawat, Abhishek Bhardwaj, Amandeep Singh, A Comprehensive Review on Indian Barnyard Millet (Echinochloa frumentacea), International Journal of Pharmaceutical Technology and Biotechnology, 2025; 12(1): 01-07.
13. Krati, Dr. Martolia Jaya, et. al, A Comprehensive review on in-vitro methods for antimicrobial activity" Educational administration: Theory and Practice". 2024; 30(6): 8 (2977-2984).

14. Esha Vatsa, Dr. Samriti Faujdar, Shilpa Chandel, Nidhi Chaudhary, Ashok Kumar, Neeru, "Studies on anti-inflammatory activities of whole plant of Dendrobium macraei Lindl." European Chemical Bulletin, 2023; 12(Special Issue 1): 657-664.
15. Esha Vatsa, Dr. Samriti Faujdar, Nitin Kumar, Nidhi Chaudhary, Shilpa Chandel, Neeru, Mehak Aggarwal "Current studies to justify the medicinal potential of the orchid Dendrobium macraei Lindl." European Chemical Bulletin, 2023; 12(S3): 5822-5830.
16. Divya Negi Rawat, Anjali Bisht, Esha Vatsa, Deepika Chandra, Nidhi Chaudhary, Ashok Kumar "Urinary bacterial profile and antibiotic susceptibility pattern among patients of urinary tract infections" High Technology letters, 2023; 29(10): 115-128.
17. Mehak Aggarwal, Ujjwal Nautiyal, Harmeet Singh, Esha Vatsa, Nidhi Chaudhary, Anjali Bisht, Divya Negi "Development and evaluation of drug delivery system containing luliconazole" High Technology letters, 2023; 29(11): 633-652.
18. Jagriti Gairola, Prashant Kukreti, Anjali Bisht, Divya Negi, Nidhi Chaudhary, Esha Vatsa "Development of Chronotherapeutic Delivery System for the Oral Administration of Aceclofenac for Rheumatoid Arthritis by Using Different Polymers" Journal of Chemical Health Risks, 2023; 13(6): 1180-1192.
19. Nidhi Chaudhary, Dr. Deepak Nanda, Dr. Esha Vatsa, Mithilesh Kesari, Harshita Chandra, Simran Singh Rathore "The Promise of Usefulness of the Evergreen Shrub Cassia auriculata" Journal of Advanced Zoology, 2023; 44(4): 1249-1261.
20. Ms Pooja Yadav, Dr. Esha Vatsa, Dr Arti Rauthan, "Enhancing Menstrual Awareness among Adolescent Girls: Evaluating the Influence of School Initiatives" Journal of Chemical Health Risks, 2024; 14(02): 3141-3149.
21. Mehak Aggarwal, Esha Vatsa, Nidhi Chaudhary, Shilpa Chandel, Shipra Gautam, "Formulation and Evaluation of Polyherbal Face Pack" Research Journal of Pharmacy and Technology, 2024; 17(6): 2481-2485.
22. Esha Vatsa, Mehak Aggarwal, Nidhi Chaudhary, Shipra Gautam, Neeru, Nitin Kumar, "Comparison Based on Pharmacognostical and Pharmacological Profile of Thuja Orientalis Linn. And Thuja Occidentalis Linn.: A Review" Naturalista Campano, 2024; 28(1): 3208-3219.
23. Priya Pandey, Esha Vatsa, Gaurav Lakhchora, Md Shamsher Alam, Niyaz Ahamad Ansari, Mohammad Dabeer Ahamad, Sarafarz Ahamad, Mukul Singh, Nitin kumar, "Nano Medicine Advancements in Addressing Rare Neurological Disorders: A Focus on Globoid Cell Leukodystrophy (Krabbe's Disease) Treatment" African Journal of Biological Sciences, 2024; 6(3): 2654-2684.
24. Esha Vatsa, Nidhi Chaudhary, Priya Khadwal, Mehak Aggarwal, Tanya Aggarwal, and Nishant Bhardwaj, "In vitro Antidiabetic Effect and Phytochemical Screening of Cassia biflora Mill." Indian Journal of Natural Sciences, 2025; 15(88): 87726-87733.
25. Anil Kumar, Dr. Esha Vatsa, "AI-Powered Embryo Selection is revolutionized: A Review" South Eastern European Journal of Public Health, 2025; XXVI (1): 6223-6230.
26. Lohani, V., A R, A., Kundu, S., Akhter, M. Q., & Bag, S. Single-Cell Proteomics with Spatial Attributes: Tools and Techniques. ACS omega, 2023; 8(20): 17499–17510. https://doi.org/10.1021/acsomega.3c00795.
27. Amandeep Singh, Deepak Nanda, Ashok Kumar and Abhishek Bhardwaj . In vitro evaluation of anti-inflammatory activity of ageratum conyzoides leaves by Human Red Blood Cell (HRBC) membrane stabilization method, International Journal of Research in Pharmaceutical and Nano Sciences, 2023; 12(6): 196-202.

28. Amandeep Singh, Deepak Nanda, Ashok Kumar, Abhishek Bhardwaj. In vitro evaluation of anti-inflammatory activity of ageratum conyzoides leaves by Human Red Blood Cell (HRBC) membrane stabilization method, International Journal of Research in Pharmaceutical and Nano Sciences, 2023; 12(6): 196-202.
29. Singh A, Nanda D, Bhardwaj A, Kumar A. A pharmacological investigation for therapeutic potential of Callistemon citrinus as an anthelmintic agent (Bottle-Brush Plant). IP Int J Comprehensive Adv Pharmacol, 2024; 9(3): 206-210.
30. Yogesh Tiwari, Amandeep Singh, Bhupendra Kumar, Ashok Kumar. "In Vitro Evaluation of Alpha Amylase Activity of Bark Extracts of Ficus Auriculata". International Journal of Innovative Science and Research Technology. December, 2017; 2(12): 88-92.
31. Bhupendra Kumar, Amandeep Singh, Yogesh Tiwari, Ashok Kumar. UV PROTECTIVE ACTIVITY OF GLYCINE MAX SEEDS. Indian Research Journal of Pharmacy and Science, 2017; 15: 1190-1195.
32. Reena Bhatt, Ashok Kumar, Ankita Sharma. FORMULATION AND EVALUATION OF SHAMPOO FORMULATED BY GLYCINE MAX SEEDS.Indian Research Journal of Pharmacy and Science, 2017; 15: 1232-1238.
33. Kumar A, Nanda D and Gupta A . "A Prospective Study on the Risk Determinants and Economic Burden ofAdverse Drug Reactions in Tertiary Care Hospital". Indian Journal of Natural Sciences, 2025; 15(88): 87957-87961.
34. Ashok Kumar, Deepak Nanda and Abhishek Gupta A holistic approach to adverse drug reactions in hospitals: Classification, risk factors, assessment and economic evaluation- A review. J. Exp. Zool. India, 2024; 27: 2337-2348. DOI: https://doi.org/10.51470/jez.2024.27.2.2337.
35. Sakshi Garg, Ashok Kumar, Varsha Deva, Preeti Biswas, Harsh Rastogi, Heena Farooqui. Immediate-Release Drug Delivery System, Current Scenario, And Future Perspective-A Narrative Review. Jundishapur Journal of Microbiology, 2022; 15(1): 6509-6519.
36. Ashok Kumar, Deepak Nanda, Abhishek Gupta Pattern of Adverse Drug Reactions and Their Economic Impact on Admitted Patients in Medicine Wards of a Tertiary Care Hospital. Library Progress International, 2024; 44(4): 1120-1139.
37. Alisha Rawat, Meenakshi Sajwan, Yamini Chandola,Nidhi Gaur "Assaultive role of thiamine in coalition with selenium in treatment of liver cancer", Journal of emerging technologies and innovative research, 2022; 9(1); 2349-5162.
38. Ghildiyal, P., Bhatt, A., Chaudhary, N., Narwal, S.,Sehgal, P. "Study of various biochemical parameters on atrazine induced glucose-6-phosphate dehydrogenase deficiency in brain" International Journal of Health Sciences, 2022; 6(S7): 2552-2558.
39. Alok Bhatt, Arun Kumar, Pallavi Ghildiyal, Jyoti Maithani, Nidhi Chaudhary, Manish Nawani, Sonia Narwal "Phytochemical Profile of Melissa parviflora Benth" Neuro Quantology, 2022; 20(9); 2426-2428.
40. Palika Sehgal, Alok Bhatt, Sonia Narwal, Deepak P. Bhagwat, Nidhi Chaudhary et.al Formulation Characterization Optimization and In Vitro Evaluation of Aceclofenac Topical Emulgel, Neuro Quantology, 2022; 20(14): 1-09.
41. Sneha Rawat, Praveen Kumar Ashok, Abhishek bhardwaj "A review on Oro dispersible Tablet of Telmisartan" Org-Journal of Emerging Technologies and Innovative research (JETIR), May 2023; 10(5): i104-i112.

42. Jaison Varghese, Nitin kumar, Sapna Chaudhar, Abhishek Bhardwaj(2024) “Comparative In-Vitro Antioxidant and Antimicrobial Potential of Some Medicinal Plants”African Journal of Biological Sciences, https://doi.org/10.48047/AFJBS.6.Si3.2024.3340-3346.
43. Asima Imtiyaz, Ajay Singh, Abhishek Bhardwaj(2024) “Green synthesis of iron oxide nanoparticles from Iris kashmiriana (Mazar-Graveyard) Plant Extract its characterization of biological activities and photocatalytic activity” Journal of Industrial and Engineering Chemistry, https://doi.org/10.1016/j.jiec.2024.09.004.
44. Hem Chandra Pant, Bhawana Goswami, Ashok Kumar, Abhishek Bhardwaj, Shanti Rauthan and Amita pandey “A Review Paper on Bacopa monniera and Role of Artificial Intelligence (AI) in Medicinal Plant for Management and Treatment of Various Diseases” Indian Journal of Natural Sciences, 2025; 15(88): 01-10.
45. Vishwajeet Bachhar, Vibha Joshi , Ajay Singh,, M. Amin Mir , Abhishek Bhardwaj(2025)“Antibacterial, Antioxidant, and Antidiabetic Activities of TiO2 Nanoparticles Synthesized Through Ultrasonication Assisted Cold Maceration from Stem Extract of Euphorbia hirta”Nano Bioscience, https://doi.org/10.33263/LIANBS141.001.
46. Nidhi Chaudhary, “A review on: The deciduous shrub “Punica granatum” , European journal of biomedical and pharmaceutical sciences, 2016; 3(7); 2349-2388.
47. Singh Harmeet and Nidhi Chaudhary, “Evaluation of Lakshadi Guggul on experimentally induced global cerebral ischemia/reperfusion injury”. World journal of Pharmacy and Pharmaceutical Sciences, 2016; 6(1); ISSN 2278-4357.
48. Nidhi Chaudhary and Harmeet Singh, “Evaluation of Punica Granatum Leaves Extract In Scopolamine Induced Learning And Memory Impairment In Mice”. World journal of Pharmacy and Pharmaceutical Sciences, 6(6); 1677-1703.
49. Amandeep Singh, Pankaj Nainwal ,Deepak Nanda ,D.A. Jain, SOLUBILITY ENHENCEMENT OF PIOGLITAZONE WITH COMPLEXATION OF HYDROXYPROPYL-β-CYCLODEXTRIN, Digest Journal of Nanomaterials and Biostructures, Apr 2012; 2(4): p.91-97.
50. Pankaj Nainwal Deepak Nanda, Amandeep Singh, D. A. Jain, QUANTITATIVE SPECTROPHOTOMETRIC DETERMINATION OF DOMPERIDONE TABLET FORMULATIONS USING IBUPROFEN SODIUM AS HYDROTROPIC SOLUBILIZING AGENT, Digest Journal of Nanomaterials and Biostructures, 2012; 2(4): 751 – 753
51. Deepak Nanda, Pankaj Nainwal, Amandeep Singh, D.A.Jain, REVIEW ON MIXED-SOLVENCY CONCEPT: A NOVEL CONCEPT OF SOLUBILIZATION, Deepak Nanda et al. ,Journal of Pharmacy Research, 2012; 3(2): 411-413
52. Pankaj Nainwal, Amandeep Singh, Deepak Nanda, D.A.Jain, NEW QUANTITATIVE ESTIMATION OF ROSUVASTATIN BULK SAMPLE USING SODIUM BENZOATE AS HYDROTROPIC SOLUBILIZING AGENT, Journal of Pharmacy Research, 2012; 3(1): 6-8
53. Nainwal.P, Bhagla.A, Nanda.D, STUDY ON ANTIOXIDANT POTENTIAL AND WOUND HEALING ACTIVITY ON THE AQUEOUS EXTRACT OF FRUITS OF GARCINIA MANGOSTANA, IJPI’s Journal of Pharmacognosy and Herbal Formulations, Volume-1
54. Pankaj Nainwal , Kapil Kalra, Deepak Nanda , Amandeep Singh, STUDY OF ANALGESIC AND ANTI-INFLAMMATORY ACTIVITIES OF THE ETHANOLIC EXTRACT ARIAL PARTS OF FUMARIA VAILLANTII LOISEL, Asian Journal of Pharmaceutical and Clinical Research, 2011; 4(1).

55. Amandeep Singh, Pankaj Nainwal , Deepak Nanda, D.A.Jain, SOLUBILITY ENHANCEMENT STUDY OF PIOGLITAZONE USING SOLID DISPERSION AS SOLUBILIZATION TECHNIQUE, International Journal of Science Innovations and Discoveries, Amandeep Singh et al., IJSID, 2011; 1(2): 95—100
56. Amandeep Singh, Pankaj Nainwal , Deepak Nanda, D. A. Jain, THE SOLUBILITY ENHANCEMENT STUDY OF PIOGLITAZONE USING DIFFERENT SOLUBLIZATION TECHNIQUIES, International Journal of Pharmacy & Pharmaceutical Sciences, 2012; 4(2).
57. Deepak Nanda, Pankaj Nainwal, Amandeep Singh, D.A.Jain, SOLUBILITY ENHANCEMENT STUDY OF DOMPERIDONE USING DIFFERENT SOLUBILIZATION TECHNIQUES, International Journal of Pharmacy and Pharmaceutical Sciences, 2012; 2(3).
58. Pankaj Nainwal, Priyanka Sinha, Amandeep Singh, Deepak Nanda, D.A.Jain, A COMPARATIVE SOLUBILITY ENHANCEMENT STUDY OF ROSUVASTATIN USING SOLUBILIZATION TECHNIQUES, International Journal of Applied Biology & Pharmaceutical Technology, Oct - Dec -2011; 2(4).
59. Pankaj Nainwal , Deepak Nanda, Amandeep Singh, D. A. Jain, FORMULATION AND EVALUATION OF SOLID DISPERSION OF ROSUVASTATIN WITH VARIOUS CARRIERS ,Pharmacie Globale International Journal Of Comprehensive Pharmacy, Issn 0976-8157.
60. Pankaj Nainwal, Amandeep Singh1, Deepak Nanda, D.A.Jain, SOLUBILITY ENHANCEMENT OF AN ANTIHYPERLIPIDEMIC DRUG ROSUVASTATIN BY SOLID DISPERSION TECHNIQUE, International Journal of PharmTech Research IJPRIF ISSN : 0974-4304, March-June 2012; 2: 3.
61. Kshitiz Agrawal, Pragati Bailwal, Amandeep Singh. Prem Saini, DEVELOPMENT OF QUALITY STANDARDS OF SUPRABHATAM CHURNA: A POLY HERBAL FORMULATION, International Journal of Pharmaceutical Research & Development,IJPRD, 2011; 4, June 2012.
62. Kapil Kalra, Amandeep Singh, Manisha Gaur, Ravindra P. Singh, and D. A. Jain, ENHANCEMENT OF BIOAVAILABLITY OF RIFAPENTINE BY SOLID DISPERSION TECHNIQUE, International Journal Of Pharmacy & Life Sciences, Kalra et al ., April, 2011; 2(4).
63. Pankaj nainwal ,Ranveer batsa, Amandeep singh, Deepak nanda, MEDICINAL PLANT STUDIES INFLUECED BY THE BIOTECHNOLOGICAL METHODS: A UPDATED REVIEW, International Journal of Pharma and Bio Sciences, Apr-June-2011; 2(2).
64. Amandeep Singh, Sandhiya Pal, Prem Saini, IN- VITRO EVALUTION OF ANTI-INFLAMMATOTRY ACTIVITY OF TERMANALIA ARJUNA BARK EXTRACT, Journal of Innovative trends in Pharmaceutical Sciences,Vol-1(1): 9-12.
65. Amandeep Singh, Pramila Chauhan, Prem Saini, IN-VITRO ANTI-INFLAMMATORY EVALUTION OF HYDROALCOHALIC LEAVES EXTACT OF PINUS ROXBURGHII BY HRBC METHOD, International journal of Research in Pharmaceutical and Nano Sciences, 2013; 2(3): 268-271.
66. Amandeep Singh, Sumit Negi, Prem Saini, In Vitro Anti-Inflammatory Evaluation Of Leaves Using Hydroalcohalic Extract Of "Mangifera indica" International Journal of Pharmacy and Integrated Life Sciences, V1-(I7) PG (93-98).
67. Aman Deep Baghla, Kshitij Agarwal, Ramesh Verma and Deepak Nanda, Wound Healing Effect of the Aqueous Extract of the Leaves of Psidium guajava Linn., International Journal of chemicals and Life Sciences, 2013; 02 (03): 1104-1106.

68. Aman Deep Baghla, Kshitij Agarwal, Ramesh Verma and Deepak Nanda, WOUND HEALING EFFECT OF THE AQUEOUS EXTRACT OF THE LEAVES OF PSIDIUM GUAJAVA LINN., International Journal of chemicals and Life Sciences, 2013; 02(03): 1104-1106.
69. Bhupendra Kumar, Meenakshi Ghildiyal, Yogesh Tiwari , Deepika Chauhan, Amandeep Singh, IN-VITRO ANTI-INFLAMMATORY ACTIVITY OF GLYCINE MAX SEEDS ,Indo American Journal Of Pharmaceutical Sciences, 2018; 05(02): 868-871.
70. Piyali Dey, Jyoti Pandey, Bhupendra kumar, Amandeep Singh, IN VITRO ANTHELMINTIC ACTIVITY OF BARK EXTRACTS OF ARTOCARPUS HETEROPHYLLUS, International Journal of Pharmacy & Pharmaceutical Research, 2018; 03(11): 33-40.
71. Bhupendra Kumar, Yogesh Tiwari, Amandeep Singh, Vineet Kumar, IN VITRO ANTIUROLITHIC ACTIVITY OF FICUS PALMATA LEAVES, International Journal Of Pharmaceutical Technology And Biotechnology, 2019; 6(1): 01-09.
72. Md. Daneyal Khurshid, Vivek Shukla, Bhupendra Kumar and Amandeep A Review Paper on Medicinal Properties of Phyllanthus emblica , International Journal of Pharmacy and Biological Sciences, 2020; 10(3): 102-109.
73. Mr. Dwivedi Vishal, Mrs. Nisha A Bhatt, Dr. Amandeep Singh PREPARATION AND STANDARDIZATION OF NAVKARSHIKA CHURNA, World Journal Of Pharmacy And Pharmaceutical Sciences, 2020; 9(8).
74. Mitun Saha1, Mr. Bhupendra Kumar, Dr. Amandeep Singh Review Article on Various Phytochemicals and Different Medicinal Activities of Haritaki International Journal of Innovative Science and Research Technology, June 2020; 5(6).